H
Henk Boot
Researcher at Netherlands Cancer Institute
Publications - 145
Citations - 10029
Henk Boot is an academic researcher from Netherlands Cancer Institute. The author has contributed to research in topics: Cancer & Hyperthermic intraperitoneal chemotherapy. The author has an hindex of 41, co-authored 145 publications receiving 8797 citations. Previous affiliations of Henk Boot include Utrecht University & Erasmus University Medical Center.
Papers
More filters
Journal ArticleDOI
Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal Cancer
Vic J. Verwaal,Serge van Ruth,Eelco de Bree,Gooike W. van Slooten,Harm van Tinteren,Henk Boot,Frans A. N. Zoetmulder +6 more
TL;DR: Cytoreduction followed by HIPEC improves survival in patients with peritoneal carcinomatosis of colorectal origin, however, patients with involvement of six or more regions of the abdominal cavity, or grossly incomplete cytoreduction, had still a grave prognosis.
Journal ArticleDOI
8-Year Follow-up of Randomized Trial: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Patients with Peritoneal Carcinomatosis of Colorectal Cancer
TL;DR: It is shown that cytoreduction followed by HIPEC does significantly add survival time to patients affected by peritoneal carcinomatosis of colorectal origin and for a selected group, there is a possibility of long-term survival.
Journal ArticleDOI
Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial
Marjolein Y.V. Homs,Ewout W. Steyerberg,W. M. H. Eijkenboom,Hugo W. Tilanus,Lukas J A Stalpers,J. F. W. M. Bartelsman,J. Jan B. van Lanschot,Harm K. Wijrdeman,Chris J. J. Mulder,Janny G. Reinders,Henk Boot,Berthe M.P. Aleman,Ernst J. Kuipers,Peter D. Siersema +13 more
TL;DR: Despite slow improvement, single-dose brachytherapy gave better long-term relief of dysphagia than metal stent placement, and is recommended as the primary treatment for palliation of dysphAGia from oesophageal cancer.
Journal ArticleDOI
Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients.
Salo N. Ooft,Fleur Weeber,Krijn K. Dijkstra,Chelsea M. McLean,Sovann Kaing,Erik van Werkhoven,Luuk J. Schipper,L.R. Hoes,Daniel J. Vis,Joris van de Haar,Warner Prevoo,Petur Snaebjornsson,Daphne L. van der Velden,Michelle Klein,Myriam Chalabi,Henk Boot,Monique E. van Leerdam,Haiko J. Bloemendal,Laurens V. Beerepoot,Lodewyk F. A. Wessels,Lodewyk F. A. Wessels,Edwin Cuppen,Hans Clevers,Emile E. Voest +23 more
TL;DR: An in vitro test based on patient-derived tumor organoids (PDOs) from metastatic lesions to identify nonresponders to standard-of-care chemotherapy in colorectal cancer (CRC) is developed and the feasibility of generating and testing PDOs for evaluation of sensitivity to chemotherapy is shown.
Journal ArticleDOI
T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication.
Hongxiang Liu,Hongtao Ye,A Ruskone-Fourmestraux,Daphne de Jong,Stefano Pileri,Christian Thiede,Anne Lavergne,Henk Boot,Giancarlo Caletti,Thomas Wündisch,Thierry Jo Molina,Babs G. Taal,Sabattini Elena,Togliani Thomas,Pier Luigi Zinzani,Andreas Neubauer,Manfred Stolte,Rifat Hamoudi,Ahmet Dogan,Peter G. Isaacson,Ming-Qing Du +20 more
TL;DR: In this paper, the translocation of gastric MALT lymphoma was detected in 2 of 48 complete-regression cases, and these positive cases showed relapse of lymphoma in the absence of H. pylori reinfection.